About us
Our company
and people
Camurus at a glance
Camurus is a Swedish science-led pharmaceutical company committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic diseases.
New medicinal products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® technology and its extensive R&D expertise. Camurus has products on the market for the treatment of opioid dependence and the clinical pipeline includes product candidates for the treatment of pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. Camurus has over 250 employees with headquarters in Lund (Sweden), and regional offices in Cambridge (UK), Mainz (Germany), Sydney (Australia) and Princeton, New Jersey (US). The company’s share is listed on Nasdaq Stockholm under the ticker “CAMX”.
our Commitment
Making a difference
Camurus focuses on developing and commercializing innovative medical products to improving the lives of patients with severe and chronic diseases.
Business model
Combining R&D expertise and world-leading technology
Streamlining development of innovative, long-acting medicines – for the benefit of patients, the healthcare system and shareholders.
Management team
Meet Camurus' management team.
Board of directors
Meet Camurus' board of directors.